{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-076825","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.451267+00:00","generated_at":"2026-05-17T14:52:42.204401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter","bullets":["Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.","Total net product revenue $15.0M, up slightly from $14.9M year-over-year.","Gross margin improved to 67% from 61% due to favorable product mix and lower COGS.","SG&A expenses rose to $11.9M from $10.3M, driven by Emrosi launch costs.","Adjusted EBITDA loss of $0.5M vs positive $0.3M in prior year period."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-076825","json":"https://secwatch.observer/filing/0001104659-25-076825.json","markdown":"https://secwatch.observer/filing/0001104659-25-076825.md","text":"https://secwatch.observer/filing/0001104659-25-076825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/0001104659-25-076825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/tm2523268d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:52:42.204401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}